Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193916 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28873134 | 0.97 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL250009 | 0.97 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| Water SCHEMBL8817645 | 0.97 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28763213 | 0.97 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL1718427 | 0.94 | ALDH1A1 (0.42) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| Cyclohexane SCHEMBL21625751 | 0.91 | ALDH1A1 (0.40) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| SCHEMBL20670455 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| SCHEMBL21788097 | 0.88 | ALDH1A1 (0.64) | ALDH1A1MAPTL3MBTL1TDP1KDM4E | |
| SCHEMBL21763039 | 0.86 | TAAR1 (0.48) | ALDH1A1MAPTL3MBTL1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421725-B2 | Alkoxyamines for the treatment of cancers | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-24 | — | — | US | disclosed |
| US-9783514-B2 | Method for preparing methylated amines | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160115130-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-04-28 | — | — | US | disclosed |
| EP-3010881-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | Centre National de la Recherche Scientifique (FR) | 2016-04-27 | — | — | EP | disclosed |
| US-9133135-B2 | Method for preparing nitrogen compounds | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20150152072-A1 | Method For Preparing Methylated Amines | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-06-04 | — | — | US | disclosed |
| US-20150148535-A1 | Method For Preparing Nitrogen Compounds | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2015-05-28 | — | — | US | disclosed |
| WO-2015001436-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-01-08 | — | — | WO | disclosed |
| US-8877971-B2 | Method for preparing formamide compounds | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-11-04 | — | — | US | disclosed |
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1852432-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148535-A1 | Method For Preparing Nitrogen Compounds | GAP43, PNPO, NT5E | ALDH1A1 1652/4885MAPT 1705/4885L3MBTL1 3504/4885 |
| US-20150152072-A1 | Method For Preparing Methylated Amines | CHRM5, KDM5A, DNMT1 | ALDH1A1 1233/4885MAPT 1159/4885L3MBTL1 2679/4885 |
| US-20160115130-A1 | ALKOXYAMINES FOR THE TREATMENT OF CANCERS | ERBB2, ALK, EGFR | ALDH1A1 62/4885MAPT 2687/4885L3MBTL1 1869/4885 |
| US-10421725-B2 | Alkoxyamines for the treatment of cancers | ERBB2, ALK, EGFR | ALDH1A1 62/4885MAPT 2687/4885L3MBTL1 1869/4885 |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CXCR1, CXCR3 | ALDH1A1 328/4885MAPT 2889/4885L3MBTL1 1455/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | ALDH1A1 334/4885MAPT 3734/4885L3MBTL1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.